Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 04/03/17 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
28 | |
| 04/03/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 04/03/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/31/17 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
   |
115 |
| 03/28/17 | 8-K | Current report filing |
|
13 | |
| 03/17/17 | EFFECT | Notice of Effectiveness |
|
1 | |
| 03/15/17 | 8-K | Current report filing |
|
4 | |
| 03/10/17 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
4 | |
| 02/15/17 | 8-K | Current report filing |
|
4 | |
| 01/25/17 | 3 | Initial statement of beneficial ownership of securities |
|
1 |
